AstraZeneca COVID-19 vaccine linked to rare spinal condition - European regulator
Dan Kitwood/Getty Images News


A safety panel of the European Medicines Agency (EMA) has recommended the addition of a rare spinal inflammation called transverse myelitis to the product information of the COVID-19 vaccine developed by AstraZeneca (NASDAQ:AZN).
The group also reiterated its recommendation of a similar warning related to the rival COVID-19 shot from Johnson & Johnson (NYSE:JNJ).

After a review of data, the EMAâs Pharmacovigilance Risk Assessment Committee (PRAC) has determined that the âcausal relationship between these two vaccines and transverse myelitis is at least a reasonable possibility.â However, the benefit-risk profiles of the vaccines remain unchanged, the panel added.
Adding to their YTD losses, COVID-19 vaccine makers are trading lower for the second straight session after top U.S. health officials questioned the urgency for shots targeted at the newly-detected Omicron variant.